

George J Bosl

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6148524/publications.pdf>

Version: 2024-02-01

173
papers

11,336
citations

20815

60
h-index

30920

102
g-index

175
all docs

175
docs citations

175
times ranked

5984
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Testicular Germ-Cell Cancer. <i>New England Journal of Medicine</i> , 1997, 337, 242-254. | 27.0 | 832 |
| 2 | TERATOMA WITH MALIGNANT TRANSFORMATION: DIVERSE MALIGNANT HISTOLOGIES ARISING IN MEN WITH GERM CELL TUMORS. <i>Journal of Urology</i> , 1998, 159, 133-138. | 0.4 | 384 |
| 3 | Combination of Paclitaxel, Ifosfamide, and Cisplatin Is an Effective Second-Line Therapy for Patients With Relapsed Testicular Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2005, 23, 6549-6555. | 1.6 | 353 |
| 4 | Phase III Randomized Trial of Conventional-Dose Chemotherapy With or Without High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Rescue As First-Line Treatment for Patients With Poor-Prognosis Metastatic Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2007, 25, 247-256. | 1.6 | 326 |
| 5 | Medical Treatment of Advanced Testicular Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2008, 299, 672. | 7.4 | 307 |
| 6 | Down-Regulation of Stem Cell Genes, Including Those in a 200-kb Gene Cluster at 12p13.31, Is Associated with In vivo Differentiation of Human Male Germ Cell Tumors. <i>Cancer Research</i> , 2006, 66, 820-827. | 0.9 | 275 |
| 7 | Long-Term and Late Effects of Germ Cell Testicular Cancer Treatment and Implications for Follow-Up. <i>Journal of Clinical Oncology</i> , 2012, 30, 3752-3763. | 1.6 | 243 |
| 8 | Paclitaxel, Ifosfamide, and Cisplatin Second-Line Therapy for Patients With Relapsed Testicular Germ Cell Cancer. <i>Journal of Clinical Oncology</i> , 2000, 18, 2413-2418. | 1.6 | 228 |
| 9 | Teratoma with malignant transformation in germ cell tumors in men. <i>Cancer</i> , 1985, 56, 860-863. | 4.1 | 225 |
| 10 | Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone, and diphenhydramine. Results of consecutive trials in 255 patients. <i>Cancer</i> , 1985, 55, 527-534. | 4.1 | 217 |
| 11 | Neoadjuvant M-Vac (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) Effect on the Primary Bladder Lesion. <i>Journal of Urology</i> , 1988, 139, 470-474. | 0.4 | 211 |
| 12 | Chemotherapy for Teratoma With Malignant Transformation. <i>Journal of Clinical Oncology</i> , 2003, 21, 4285-4291. | 1.6 | 211 |
| 13 | TI-CE High-Dose Chemotherapy for Patients With Previously Treated Germ Cell Tumors: Results and Prognostic Factor Analysis. <i>Journal of Clinical Oncology</i> , 2010, 28, 1706-1713. | 1.6 | 192 |
| 14 | Sequential Dose-Intensive Paclitaxel, Ifosfamide, Carboplatin, and Etoposide Salvage Therapy for Germ Cell Tumor Patients. <i>Journal of Clinical Oncology</i> , 2000, 18, 1173-1180. | 1.6 | 187 |
| 15 | Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Testicular Cancer: Impact of Patient Selection Factors on Outcome. <i>Journal of Clinical Oncology</i> , 2005, 23, 2781-2788. | 1.6 | 185 |
| 16 | CT Findings of Chemotherapy-induced Toxicity: What Radiologists Need to Know about the Clinical and Radiologic Manifestations of Chemotherapy Toxicity. <i>Radiology</i> , 2011, 258, 41-56. | 7.3 | 180 |
| 17 | Surgery for a Post-Chemotherapy Residual Mass in Seminoma. <i>Journal of Urology</i> , 1997, 157, 860-862. | 0.4 | 157 |
| 18 | Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation. <i>Oncogene</i> , 1998, 16, 2345-2349. | 5.9 | 148 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Genetic Determinants of Cisplatin Resistance in Patients With Advanced Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2016, 34, 4000-4007. | 1.6 | 147 |
| 20 | Molecular cytogenetic analysis of i(12p)-negative human male germ cell tumors. <i>Genes Chromosomes and Cancer</i> , 1993, 8, 230-236. | 2.8 | 141 |
| 21 | CLINICAL STAGE I TESTIS CANCER: LONG-TERM OUTCOME OF PATIENTS ON SURVEILLANCE. <i>Journal of Urology</i> , 1998, 159, 855-858. | 0.4 | 137 |
| 22 | Incidence of Metastatic Nonseminomatous Germ Cell Tumor Outside the Boundaries of a Modified Postchemotherapy Retroperitoneal Lymph Node Dissection. <i>Journal of Clinical Oncology</i> , 2007, 25, 4365-4369. | 1.6 | 132 |
| 23 | Salvage chemotherapy for patients with germ cell tumors. The memorial sloan-kettering cancer center experience (1979-1989). <i>Cancer</i> , 1991, 67, 1305-1310. | 4.1 | 127 |
| 24 | Role of promoter hypermethylation in Cisplatin treatment response of male germ cell tumors. <i>Molecular Cancer</i> , 2004, 3, 16. | 19.2 | 125 |
| 25 | The role of ifosfamide plus cisplatin-based chemotherapy as salvage therapy for patients with refractory germ cell tumors. <i>Cancer</i> , 1990, 66, 2476-2481. | 4.1 | 119 |
| 26 | Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin Plus Etoposide in Previously Treated Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2007, 26, 85-90. | 1.6 | 119 |
| 27 | Nonrandomized Comparison of Primary Chemotherapy and Retroperitoneal Lymph Node Dissection for Clinical Stage IIA and IIB Nonseminomatous Germ Cell Testicular Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 5597-5602. | 1.6 | 114 |
| 28 | Acute Nonlymphocytic Leukemia in Germ Cell Tumor Patients Treated With Etoposide-Containing Chemotherapy. <i>Journal of the National Cancer Institute</i> , 1993, 85, 60-62. | 6.3 | 112 |
| 29 | Leukemic differentiation of a mediastinal germ cell tumor. <i>Genes Chromosomes and Cancer</i> , 1989, 1, 83-87. | 2.8 | 109 |
| 30 | Clinical Outcome and Predictors of Survival in Late Relapse of Germ Cell Tumor. <i>Journal of Clinical Oncology</i> , 2008, 26, 5524-5529. | 1.6 | 107 |
| 31 | High-dose chemotherapy and autologous bone marrow rescue for patients with refractory germ cell tumors. Early intervention is better tolerated. <i>Cancer</i> , 1992, 69, 550-556. | 4.1 | 105 |
| 32 | Resection of postchemotherapy residual masses and limited retroperitoneal lymphadenectomy in patients with metastatic testicular nonseminomatous germ cell tumors. <i>Cancer</i> , 1994, 74, 1329-1334. | 4.1 | 105 |
| 33 | RETROPERITONEAL LYMPH NODE DISSECTION IN PATIENTS WITH LOW STAGE TESTICULAR CANCER WITH EMBRYONAL CARCINOMA PREDOMINANCE AND/OR LYMPHOVASCULAR INVASION. <i>Journal of Urology</i> , 2005, 174, 557-560. | 0.4 | 103 |
| 34 | Combined chemotherapy and radiotherapy versus surgery and postoperative radiotherapy for advanced hypopharyngeal cancer. <i>Head and Neck</i> , 1996, 18, 405-411. | 2.0 | 100 |
| 35 | Role of Postchemotherapy Adjunctive Surgery in the Management of Patients With Nonseminoma Arising From the Mediastinum. <i>Journal of Clinical Oncology</i> , 2001, 19, 682-688. | 1.6 | 99 |
| 36 | Characteristic promoter hypermethylation signatures in male germ cell tumors. <i>Molecular Cancer</i> , 2002, 1, 8. | 19.2 | 99 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Long-Term Clinical Outcome After Postchemotherapy Retroperitoneal Lymph Node Dissection in Men With Residual Teratoma. <i>Journal of Clinical Oncology</i> , 2007, 25, 1033-1037. | 1.6 | 99 |
| 38 | Extragenital and poor risk nonseminomatous germ cell tumors. Survival and prognostic features. <i>Cancer</i> , 1991, 67, 2049-2057. | 4.1 | 97 |
| 39 | Incidence of Disease Outside Modified Retroperitoneal Lymph Node Dissection Templates in Clinical Stage I or IIA Nonseminomatous Germ Cell Testicular Cancer. <i>Journal of Urology</i> , 2007, 177, 937-943. | 0.4 | 97 |
| 40 | Low-Volume Nodal Metastases Detected at Retroperitoneal Lymphadenectomy for Testicular Cancer: Pattern and Prognostic Factors for Relapse. <i>Journal of Clinical Oncology</i> , 2001, 19, 2020-2025. | 1.6 | 95 |
| 41 | Improved Clinical Outcome in Recent Years for Men With Metastatic Nonseminomatous Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2007, 25, 5603-5608. | 1.6 | 92 |
| 42 | Etoposide and Cisplatin Chemotherapy for Metastatic Good-Risk Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2005, 23, 9290-9294. | 1.6 | 91 |
| 43 | Relapse-Free and Overall Survival in Patients With Pathologic Stage II Nonseminomatous Germ Cell Cancer Treated With Etoposide and Cisplatin Adjuvant Chemotherapy. <i>Journal of Clinical Oncology</i> , 2004, 22, 464-467. | 1.6 | 90 |
| 44 | Surgical resection of solitary metastases after chemotherapy in patients with nonseminomatous germ cell tumors and elevated serum tumor markers. <i>Cancer</i> , 1992, 70, 2354-2357. | 4.1 | 88 |
| 45 | Presence of Somatic Mutations within <i>PIK3CA</i> , <i>AKT</i> , <i>RAS</i> , and <i>FGFR3</i> but not <i>BRAF</i> in Cisplatin-Resistant Germ Cell Tumors. <i>Clinical Cancer Research</i> , 2014, 20, 3712-3720. | 7.0 | 88 |
| 46 | Amplification of the 3q26.3 Locus Is Associated with Progression to Invasive Cancer and Is a Negative Prognostic Factor in Head and Neck Squamous Cell Carcinomas. <i>American Journal of Pathology</i> , 2002, 161, 365-371. | 3.8 | 86 |
| 47 | Reoperative retroperitoneal surgery for nonseminomatous germ cell tumor: clinical presentation, patterns of recurrence, and outcome. <i>Urology</i> , 2003, 62, 732-736. | 1.0 | 86 |
| 48 | Testicular mixed germ cell tumors: a morphological and immunohistochemical study using stem cell markers, OCT3/4, SOX2 and GDF3, with emphasis on morphologically difficult-to-classify areas. <i>Modern Pathology</i> , 2009, 22, 1066-1074. | 5.5 | 85 |
| 49 | Testicular Seminoma: A Clinicopathologic and Immunohistochemical Study of 105 Cases with Special Reference to Seminomas with Atypical Features. <i>International Journal of Surgical Pathology</i> , 2002, 10, 23-32. | 0.8 | 84 |
| 50 | Sequential excision of residual thoracic and retroperitoneal masses after chemotherapy for stage III germ cell tumors. <i>Cancer</i> , 1986, 57, 978-983. | 4.1 | 81 |
| 51 | Reduced Proficiency in Homologous Recombination Underlies the High Sensitivity of Embryonal Carcinoma Testicular Germ Cell Tumors to Cisplatin and Poly (ADP-Ribose) Polymerase Inhibition. <i>PLoS ONE</i> , 2012, 7, e51563. | 2.5 | 78 |
| 52 | Incidence of Late-Relapse Germ Cell Tumor and Outcome to Salvage Chemotherapy. <i>Journal of Clinical Oncology</i> , 2005, 23, 6999-7004. | 1.6 | 77 |
| 53 | Biology and Genetics of Adult Male Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2006, 24, 5512-5518. | 1.6 | 73 |
| 54 | Pathologic findings and clinical outcome of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy regimens for metastatic testicular germ cell tumors. <i>Cancer</i> , 2007, 109, 528-535. | 4.1 | 73 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | The Management of Patients with Nonseminomatous Germ Cell Tumors of the Testis with Serologic Disease Only After Orchiectomy. <i>Journal of Urology</i> , 1994, 152, 111-113. | 0.4 | 71 |
| 56 | Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage chemotherapy. <i>Cancer</i> , 1994, 73, 2520-2526. | 4.1 | 70 |
| 57 | Predicting Teratoma in the Retroperitoneum in Men Undergoing Post-Chemotherapy Retroperitoneal Lymph Node Dissection. <i>Journal of Urology</i> , 2006, 176, 100-104. | 0.4 | 70 |
| 58 | Identification and Validation of a Gene Expression Signature That Predicts Outcome in Adult Men With Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2009, 27, 5240-5247. | 1.6 | 70 |
| 59 | Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors. <i>Investigational New Drugs</i> , 2010, 28, 523-528. | 2.6 | 66 |
| 60 | Abnormalities of 2q: A common genetic link between rhabdomyosarcoma and hepatoblastoma?. <i>Genes Chromosomes and Cancer</i> , 1991, 3, 122-127. | 2.8 | 62 |
| 61 | Alteration of p53 Pathway in Squamous Cell Carcinoma of the Head and Neck: Impact on Treatment Outcome in Patients Treated With Larynx Preservation Intent. <i>Journal of Clinical Oncology</i> , 2002, 20, 2980-2987. | 1.6 | 61 |
| 62 | Gene expression-based classification of nonseminomatous male germ cell tumors. <i>Oncogene</i> , 2005, 24, 5101-5107. | 5.9 | 57 |
| 63 | Concomitant chemotherapy-radiation therapy followed by hyperfractionated radiation therapy for advanced unresectable head and neck cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 1991, 21, 703-708. | 0.8 | 56 |
| 64 | Incidence and Clinical Outcome of Patients with Teratoma in the Retroperitoneum Following Primary Retroperitoneal Lymph Node Dissection for Clinical Stages I and IIA Nonseminomatous Germ Cell Tumors. <i>Journal of Urology</i> , 2003, 170, 1159-1162. | 0.4 | 56 |
| 65 | Practice Makes Perfect: The Rest of the Story in Testicular Cancer as a Model Curable Neoplasm. <i>Journal of Clinical Oncology</i> , 2017, 35, 3525-3528. | 1.6 | 56 |
| 66 | Tumor markers in advanced nonseminomatous testicular cancer. <i>Cancer</i> , 1981, 47, 572-576. | 4.1 | 55 |
| 67 | Human chorionic gonadotropin and alphafetoprotein in the staging of nonseminomatous testicular cancer. <i>Cancer</i> , 1981, 47, 328-332. | 4.1 | 54 |
| 68 | Larynx Preservation with Combined Chemotherapy and Radiation Therapy in Advanced Hypopharynx Cancer. <i>Otolaryngology - Head and Neck Surgery</i> , 1994, 111, 31-37. | 1.9 | 54 |
| 69 | Progression-free and overall survival in patients with relapsed/refractory germ cell tumors treated with single-agent chemotherapy: Endpoints for clinical trial design. <i>Cancer</i> , 2012, 118, 981-986. | 4.1 | 50 |
| 70 | Clinical Outcomes of Local and Metastatic Testicular Sex Cord-Stromal Tumors. <i>Journal of Urology</i> , 2014, 192, 415-419. | 0.4 | 49 |
| 71 | The Total Number of Retroperitoneal Lymph Nodes Resected Impacts Clinical Outcome After Chemotherapy for Metastatic Testicular Cancer. <i>Urology</i> , 2010, 75, 1431-1435. | 1.0 | 47 |
| 72 | Analysis of chromosome 12 aneuploidy in interphase cells from human male germ cell tumors by fluorescence in situ hybridization. <i>Genes Chromosomes and Cancer</i> , 1992, 5, 21-29. | 2.8 | 46 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Phase I Study of Flavopiridol with Oxaliplatin and Fluorouracil/Leucovorin in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2009, 15, 7405-7411. | 7.0 | 44 |
| 74 | A prospective phase ii trial of concomitant chemotherapy and radiotherapy with delayed accelerated fractionation in unresectable tumors of the head and neck. , 1998, 20, 497-503. | | 43 |
| 75 | Does Size Matter? Association Between Number of Patients Treated and Patient Outcome in Metastatic Testicular Cancer. <i>Journal of the National Cancer Institute</i> , 1999, 91, 816-818. | 6.3 | 42 |
| 76 | Resection of Primary Mediastinal Non-Seminomatous Germ Cell Tumors: A 28-Year Experience at Memorial Sloan-Kettering Cancer Center. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1236-1241. | 1.1 | 42 |
| 77 | Two-drug therapy in patients with metastatic germ cell tumors. <i>Cancer</i> , 1991, 67, 28-32. | 4.1 | 41 |
| 78 | Tumor classification and size in germ-cell testicular cancer. Influence on the occurrence of metastases. <i>Cancer</i> , 1982, 50, 1591-1595. | 4.1 | 40 |
| 79 | Carboplatin, etoposide, and bleomycin for patients with poor-risk germ cell tumors. <i>Cancer</i> , 1990, 65, 2465-2470. | 4.1 | 37 |
| 80 | RECOGNIZING ABNORMAL MARKER RESULTS THAT DO NOT REFLECT DISEASE IN PATIENTS WITH GERM CELL TUMORS. <i>Journal of Urology</i> , 2000, 163, 796-801. | 0.4 | 37 |
| 81 | Physical Mapping of a Commonly Deleted Region, the Site of a Candidate Tumor Suppressor Gene, at 12q22 in Human Male Germ Cell Tumors. <i>Genomics</i> , 1996, 35, 562-570. | 2.9 | 36 |
| 82 | Scientific Review of Phase I Protocols With Novel Dose-Escalation Designs: How Much Information Is Needed?. <i>Journal of Clinical Oncology</i> , 2015, 33, 2221-2225. | 1.6 | 35 |
| 83 | Development of a risk stratification system to guide treatment for female germ cell tumors. <i>Gynecologic Oncology</i> , 2015, 138, 566-572. | 1.4 | 34 |
| 84 | Platinum-DNA adducts assayed in leukocytes of patients with germ cell tumors measured by atomic absorbance spectrometry and enzyme-linked immunosorbent assay. <i>Cancer</i> , 1994, 73, 2843-2852. | 4.1 | 33 |
| 85 | Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour. <i>BJU International</i> , 2007, 99, 993-997. | 2.5 | 33 |
| 86 | Decompression of epidural metastases from germ cell tumors with chemotherapy. <i>Journal of Neuro-Oncology</i> , 1990, 8, 275-80. | 2.9 | 32 |
| 87 | Double-Blind, Placebo-Controlled, Randomized Trial of Granulocyte-Colony Stimulating Factor During Postoperative Radiotherapy for Squamous Head and Neck Cancer. <i>Cancer Journal (Sudbury, Tj ETQq1 1 0.784314 rg3E /Overl</i> | 1.4 | 32 |
| 88 | Interrogation of a Context-Specific Transcription Factor Network Identifies Novel Regulators of Pluripotency. <i>Stem Cells</i> , 2015, 33, 367-377. | 3.2 | 32 |
| 89 | VP-16 and cisplatin in the treatment of patients with refractory germ cell tumors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1984, 7, 327-330. | 1.3 | 31 |
| 90 | Sarcoidosis, sarcoid-like lymphadenopathy, and testicular germ cell tumors. <i>American Journal of Medicine</i> , 1990, 89, 651-656. | 1.5 | 31 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | FGF4 dissociates anti-tumorigenic from differentiation signals of retinoic acid in human embryonal carcinomas. <i>Oncogene</i> , 1998, 17, 761-767. | 5.9 | 31 |
| 92 | Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients With Intermediate- or Poor-Risk Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2016, 34, 2478-2483. | 1.6 | 31 |
| 93 | all-trans retinoic acid for treating germ cell tumors. In vitro activity and results of a phase II trial. <i>Cancer</i> , 1995, 76, 680-686. | 4.1 | 30 |
| 94 | Clinical features, presentation, and tolerance of platinum-based chemotherapy in germ cell tumor patients 50 years of age and older. <i>Cancer</i> , 2013, 119, 2574-2581. | 4.1 | 30 |
| 95 | Clinical outcome after retroperitoneal lymphadenectomy of patients with pure testicular teratoma. <i>Urology</i> , 2003, 62, 1092-1096. | 1.0 | 29 |
| 96 | Phase II trial of topotecan in patients with cisplatin-refractory germ cell tumors. <i>Investigational New Drugs</i> , 1995, 13, 163-165. | 2.6 | 28 |
| 97 | Clinical Impact of Residual Extraperitoneal Masses in Patients With Advanced Nonseminomatous Germ Cell Testicular Cancer. <i>Urology</i> , 2012, 79, 156-159. | 1.0 | 28 |
| 98 | Predicting Cardiovascular Disease Among Testicular Cancer Survivors After Modern Cisplatin-based Chemotherapy: Application of the Framingham Risk Score. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e761-e769. | 1.9 | 28 |
| 99 | Molecular events in germ cell tumours: linking chromosome 12 gain, acquisition of pluripotency and response to cisplatin. <i>BJU International</i> , 2009, 104, 1334-1338. | 2.5 | 27 |
| 100 | Optimal Management of Clinical Stage I Testis Cancer: One Size Does Not Fit All. <i>Journal of Clinical Oncology</i> , 2013, 31, 3477-3479. | 1.6 | 27 |
| 101 | Suramin for germ cell tumors. In vitro growth inhibition and results of a phase II trial. <i>Cancer</i> , 1993, 72, 3313-3317. | 4.1 | 26 |
| 102 | Cluster Analysis of p53 and Ki67 Expression, Apoptosis, Alpha-Fetoprotein, and Human Chorionic Gonadotrophin Indicates a Favorable Prognostic Subgroup Within the Embryonal Carcinoma Germ Cell Tumor. <i>Journal of Clinical Oncology</i> , 2003, 21, 2679-2688. | 1.6 | 25 |
| 103 | Evaluation of lymph node counts in primary retroperitoneal lymph node dissection. <i>Cancer</i> , 2010, 116, 5243-5250. | 4.1 | 25 |
| 104 | Results of Retroperitoneal Lymph Node Dissection for Clinical Stage I and II Pure Embryonal Carcinoma of the Testis. <i>Journal of Urology</i> , 2003, 170, 1155-1158. | 0.4 | 24 |
| 105 | Expression profiling of lineage differentiation in pluripotential human embryonal carcinoma cells. <i>Cell Growth & Differentiation: the Molecular Biology Journal of the American Association for Cancer Research</i> , 2002, 13, 257-64. | 0.8 | 24 |
| 106 | Carboplatin in Clinical Stage I Seminoma: Too Much and Too Little at the Same Time. <i>Journal of Clinical Oncology</i> , 2011, 29, 949-952. | 1.6 | 23 |
| 107 | The indication for postchemotherapy lymph node dissection in clinical stage IS nonseminomatous germ cell tumor. <i>Cancer</i> , 2008, 112, 800-805. | 4.1 | 22 |
| 108 | A 3-Mb High-Resolution BAC/PAC Contig of 12q22 Encompassing the 830-kb Consensus Minimal Deletion in Male Germ Cell Tumors. <i>Genome Research</i> , 1999, 9, 662-671. | 5.5 | 22 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | Impact of symptomatic interval on prognosis of patients with stage III testicular cancer. <i>Urology</i> , 1983, 21, 559-561. | 1.0 | 21 |
| 110 | Serum tumor markers and patient allocation to good-risk and poor-risk clinical trials in patients with germ cell tumors. <i>Cancer</i> , 1991, 67, 1299-1304. | 4.1 | 21 |
| 111 | Phase II Trial of ixabepilone in patients with cisplatin-refractory germ cell tumors. <i>Investigational New Drugs</i> , 2007, 25, 487-490. | 2.6 | 21 |
| 112 | Rare De Novo Germline Copy-Number Variation in Testicular Cancer. <i>American Journal of Human Genetics</i> , 2012, 91, 379-383. | 6.2 | 21 |
| 113 | Primary Retroperitoneal Lymph Node Dissection in Low-stage Testicular Germ Cell Tumors: A Detailed Pathologic Study With Clinical Outcome Analysis With Special Emphasis on Patients Who Did Not Receive Adjuvant Therapy. <i>Urology</i> , 2013, 82, 1341-1347. | 1.0 | 21 |
| 114 | Transcriptional program of bone morphogenetic protein-2-induced epithelial and smooth muscle differentiation of pluripotent human embryonal carcinoma cells. <i>Functional and Integrative Genomics</i> , 2005, 5, 59-69. | 3.5 | 20 |
| 115 | Rates of Teratoma and Viable Cancer at Post-Chemotherapy Retroperitoneal Lymph Node Dissection after Induction Chemotherapy for Good Risk Nonseminomatous Germ Cell Tumors. <i>Journal of Urology</i> , 2015, 193, 513-518. | 0.4 | 20 |
| 116 | Carboplatin for Stage I Seminoma and the Sword of Damocles. <i>Journal of Clinical Oncology</i> , 2005, 23, 8566-8569. | 1.6 | 19 |
| 117 | Time to publication of oncology trials and why some trials are never published. <i>PLoS ONE</i> , 2017, 12, e0184025. | 2.5 | 19 |
| 118 | Interrelationships of histopathology and other clinical variables in patients with germ cell tumors of the testis. <i>Cancer</i> , 1983, 51, 2121-2125. | 4.1 | 18 |
| 119 | Development and Validation of a Gene-Based Model for Outcome Prediction in Germ Cell Tumors Using a Combined Genomic and Expression Profiling Approach. <i>PLoS ONE</i> , 2015, 10, e0142846. | 2.5 | 18 |
| 120 | Malignant carcinoid of the gallbladder: Third reported case and review of the literature. <i>Journal of Surgical Oncology</i> , 1980, 13, 215-222. | 1.7 | 17 |
| 121 | Impact of Teratoma on the Cumulative Incidence of Disease-Related Death in Patients With Advanced Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2019, 37, 2329-2337. | 1.6 | 17 |
| 122 | A Review of Second-line Chemotherapy and Prognostic Models for Disseminated Germ Cell Tumors. <i>Hematology/Oncology Clinics of North America</i> , 2011, 25, 557-576. | 2.2 | 16 |
| 123 | Body Mass Index Is Associated With Higher Lymph Node Counts During Retroperitoneal Lymph Node Dissection. <i>Urology</i> , 2012, 79, 361-364. | 1.0 | 16 |
| 124 | ROLE OF ADJUVANT CHEMOTHERAPY IN PATIENTS WITH STAGE II NONSEMINOMATOUS GERM-CELL TUMORS. <i>Urologic Clinics of North America</i> , 1993, 20, 111-116. | 1.8 | 16 |
| 125 | miR-18b and miR-518b Target <i>FOXN1</i> During Epithelial Lineage Differentiation in Pluripotent Cells. <i>Stem Cells and Development</i> , 2014, 23, 1149-1156. | 2.1 | 15 |
| 126 | Controversies in the Management of Clinical Stage I Seminoma: Carboplatin a Decade in "Time to Start Backing Out. <i>Journal of Clinical Oncology</i> , 2018, 36, 837-840. | 1.6 | 15 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 127 | Weighing Risks and Benefits of Postchemotherapy Retroperitoneal Lymph Node Dissection: Not So Easy. <i>Journal of Clinical Oncology</i> , 2010, 28, 519-521. | 1.6 | 14 |
| 128 | Contemporary Lymph Node Counts During Primary Retroperitoneal Lymph Node Dissection. <i>Urology</i> , 2011, 77, 368-372. | 1.0 | 14 |
| 129 | Phase II study of iproplatin (CHIP) in patients with cisplatin-refractory germ cell tumors; the need for alternative strategies in the investigation of new agents in GCT. <i>Investigational New Drugs</i> , 1992, 10, 327-330. | 2.6 | 13 |
| 130 | High-dose chemotherapy as primary treatment for poor-risk germ-cell tumors: The Memorial Sloan-Kettering experience (1988-1999)., 1999, 83, 834-838. | | 12 |
| 131 | Phase II Trial of Temozolomide in Patients with Cisplatin-Refractory Germ Cell Tumors. <i>Investigational New Drugs</i> , 2004, 22, 177-179. | 2.6 | 12 |
| 132 | Constitutive Gene Expression Predisposes Morphogen-Mediated Cell Fate Responses of NT2/D1 and 27X-1 Human Embryonal Carcinoma Cells. <i>Stem Cells</i> , 2007, 25, 771-778. | 3.2 | 12 |
| 133 | Bilateral Testicular Germ Cell Tumors in the Era of Multimodal Therapy. <i>Urology</i> , 2017, 103, 154-160. | 1.0 | 12 |
| 134 | Clinical Outcome of Retroperitoneal Lymph Node Dissection after Chemotherapy in Patients with Pure Embryonal Carcinoma in the Orchiectomy Specimen. <i>Urology</i> , 2018, 114, 133-138. | 1.0 | 12 |
| 135 | Adjuvant Chemotherapy With Etoposide Plus Cisplatin for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2020, 38, 1332-1337. | 1.6 | 11 |
| 136 | Outcomes After Resection of Postchemotherapy Residual Neck Mass in Patients With Germ Cell Tumors—An Update. <i>Urology</i> , 2011, 77, 655-659. | 1.0 | 10 |
| 137 | Treatment of epidural spinal cord involvement from germ cell tumors with chemotherapy. <i>Cancer</i> , 2011, 117, 1911-1916. | 4.1 | 10 |
| 138 | Clinical Outcome of Patients with Fibrosis/Necrosis at Post-Chemotherapy Retroperitoneal Lymph Node Dissection for Advanced Germ Cell Tumors. <i>Journal of Urology</i> , 2017, 197, 391-397. | 0.4 | 10 |
| 139 | Germ cell tumor clinical trials in North America. , 1999, 17, 257-262. | | 9 |
| 140 | Germ Cell Tumor Molecular Heterogeneity Revealed Through Analysis of Primary and Metastasis Pairs. <i>JCO Precision Oncology</i> , 2020, 4, 1307-1320. | 3.0 | 9 |
| 141 | 830: Clinical Outcome Following Post-Chemotherapy Retroperitoneal Lymph Node Dissection for Men with CII Non-Seminomatous Germ Cell Tumors and a Radiographically Normal Retroperitoneum. <i>Journal of Urology</i> , 2007, 177, 277-277. | 0.4 | 9 |
| 142 | Outcomes After Multidisciplinary Management of Primary Mediastinal Germ Cell Tumors. <i>Annals of Surgery</i> , 2021, 274, e1099-e1107. | 4.2 | 9 |
| 143 | Phase II trial of pyrazoloacridine in patients with cisplatin-refractory germ cell tumors. <i>Investigational New Drugs</i> , 2000, 18, 265-267. | 2.6 | 8 |
| 144 | Impact of age on clinicopathological outcomes and recurrence-free survival after the surgical management of nonseminomatous germ cell tumour. <i>BJU International</i> , 2012, 110, 950-955. | 2.5 | 8 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 145 | Mechanism and Role of SOX2 Repression in Seminoma: Relevance to Human Germline Specification. <i>Stem Cell Reports</i> , 2016, 6, 772-783. | 4.8 | 8 |
| 146 | Four Cycles of Etoposide plus Cisplatin for Patients with Good-Risk Advanced Germ Cell Tumors. <i>Oncologist</i> , 2021, 26, 483-491. | 3.7 | 8 |
| 147 | Treatment of stage I seminoma: is it time to change your practice?. <i>Journal of Hematology and Oncology</i> , 2008, 1, 22. | 17.0 | 7 |
| 148 | Histologic and Oncologic Outcomes Following Liver Mass Resection With Retroperitoneal Lymph Node Dissection in Patients With Nonseminomatous Germ Cell Tumor. <i>Urology</i> , 2018, 118, 114-118. | 1.0 | 7 |
| 149 | Altering the Natural History of Surgical Relapse in Testicular Cancer: Suboptimal Surgery and Pneumoperitoneum. <i>European Urology</i> , 2019, 76, 612-614. | 1.9 | 7 |
| 150 | Infectious Complications from High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Metastatic Germ Cell Tumors. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 595-600. | 2.0 | 6 |
| 151 | Pelvic Lymph Node Dissection in Patients Treated for Testis Cancer: The Memorial Sloan Kettering Cancer Center Experience. <i>Urology</i> , 2016, 95, 128-131. | 1.0 | 6 |
| 152 | Surgical Management of Patients with Advanced Germ Cell Tumors Following Salvage Chemotherapy: Memorial Sloan Kettering Cancer Center (MSKCC) Experience.. <i>Urology</i> , 2019, 124, 174-178. | 1.0 | 6 |
| 153 | Outcomes in Patients With Clinical Stage III NSGCT Who Achieve Complete Clinical Response to Chemotherapy at Extraretroperitoneal Disease Site. <i>Urology</i> , 2012, 79, 1079-1084. | 1.0 | 5 |
| 154 | Phase I/II Trial of Paclitaxel With Ifosfamide Followed by High-Dose Paclitaxel, Ifosfamide, and Carboplatin (TI-TIC) With Autologous Stem Cell Reinfusion for Salvage Treatment of Germ Cell Tumors. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 453-460. | 1.9 | 5 |
| 155 | Status and prospects of the treatment of disseminated germ-cell tumors. <i>World Journal of Urology</i> , 1984, 2, 38-42. | 2.2 | 4 |
| 156 | The future of therapy for nonseminomatous germ cell tumors. <i>Chest Surgery Clinics of North America</i> , 2002, 12, 769-789. | 0.7 | 4 |
| 157 | Thoracic Metastasectomy in Germ Cell Tumor Patients Treated With First-line Versus Salvage Therapy. <i>Annals of Thoracic Surgery</i> , 2021, 111, 1141-1149. | 1.3 | 4 |
| 158 | Surgery of Testicular Tumors. , 2012, , 871-892.e6. | | 4 |
| 159 | Abnormal colony formation and prostaglandin e responsiveness of myeloid progenitor cells in patients cured of germ cell neoplasms after combination chemotherapy. <i>Cancer</i> , 1987, 60, 312-317. | 4.1 | 3 |
| 160 | Expression of ID Genes in Differentiated Elements of Human Male Germ Cell Tumors. <i>Diagnostic Molecular Pathology</i> , 2001, 10, 248-254. | 2.1 | 3 |
| 161 | The Current Status of Salvage Chemotherapy for Patients with Cisplatin-Resistant Germ Cell Tumors. <i>Cancer Investigation</i> , 1993, 11, 94-96. | 1.3 | 2 |
| 162 | Recurrent Germ Cell Tumors: Let's Try to Cure Them All. <i>Journal of Oncology Practice</i> , 2016, 12, 445-447. | 2.5 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 163 | Advances in Urologic Oncology: Results Progress From Successful Interdisciplinary Research. Journal of Clinical Oncology, 2006, 24, 5479-5481. | 1.6 | 1 |
| 164 | Reply to L.H. Einhorn et al. Journal of Clinical Oncology, 2010, 28, e740-e740. | 1.6 | 1 |
| 165 | Testicular granulosa cell tumors: rare tumors need to be studied too. Oncology, 2009, 23, 796. | 0.5 | 1 |
| 166 | Genetics and Biology of Adult Male Germ Cell Tumors. , 2005, , 221-229. | | 0 |
| 167 | Curing germ cell tumors after failure of high-dose chemotherapy: progress through clinical trials. Nature Clinical Practice Oncology, 2007, 4, 508-509. | 4.3 | 0 |
| 168 | Reply to S. Stenning et al and J. Lipshitz. Journal of Clinical Oncology, 2011, 29, 4211-4212. | 1.6 | 0 |
| 169 | Reply. Urology, 2013, 82, 1346-1347. | 1.0 | 0 |
| 170 | Germ Cell Tumors: Looking to the Future. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e253-e258. | 3.8 | 0 |
| 171 | Reply to L.H. Einhorn et al. Journal of Clinical Oncology, 2020, 38, 3074-3075. | 1.6 | 0 |
| 172 | Germ Cell Tumors. , 2002, , 287-296. | | 0 |
| 173 | Advances in the Understanding of Germ Cell Tumour Biology. , 2002, , 23-29. | | 0 |